Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Investigation of the mechanism of Astragalus membranaceus in the treatment of lumbar disc herniation using network pharmacology

WenJie Ke¹, Chengwei Yu² , Wei Liu³, Haifeng Liu²

¹Department of Nursing, Wenzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University, Wenzhou, Zhejiang Province 325000, China; ²Department of Orthopedics, Wenzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University, Wenzhou, Zhejiang Province 325000, China; ³Department of Rehabilitation, Wenzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University, Wenzhou, Zhejiang Province 325000, China.

For correspondence:- Chengwei Yu Email: yuchengwei3050901@163.com Tel:+8615990703003

Accepted: 27 August 2023 Published: 30 September 2023

Citation: Ke W, Yu C, Liu W, Liu H. Investigation of the mechanism of Astragalus membranaceus in the treatment of lumbar disc herniation using network pharmacology. Trop J Pharm Res 2023; 22(9):1815-1822 doi: 10.4314/tjpr.v22i9.7

© 2023 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To determine the underlying mechanisms of action of Astragalus membranaceus in lumbar disc herniation (LDH) treatment.

Methods: This study utilized network pharmacology analysis and STRING database to identify compound targets and visualize PPI network. Furthermore, an LDH model was induced in human nucleus pulposus cells using lipopolysaccharide (LPS), and then the vital target genes were evaluated in this model treated with active components of Astragalus membranaceus.

Results: Network pharmacology analysis indicates that several key proteins, including vascular endothelial growth factor A (VEGF A), AKT1, JUN, prostaglandin-endoperoxide synthase 2 (PTGS2), interleukin-6 (IL-6), matrix metallopeptidase 9 (MMP9), interleukin-1β (IL-1β), C-X-C motif chemokine ligand 8 (CXCL8), epidermal growth factor (EGF) and matrix metallopeptidase 2 (MMP2) may play essential roles in LDH treated with Astragalus membranaceus. The active components in Astragalus membranaceus suppressed the production of IL-1β and IL-6, and increased the expressions of VEGF A, MMP9 and MMP2 in LPS-induced LDH model.

Conclusion: The active components of Astragalus membranaceus effectively inhibits inflammation in LPS-induced LDH model, indicating that Astragalus membranaceus is a potential therapeutic candidate for LDH treatment.

Keywords: Astragalus membranaceus, Inflammation, Lumbar disc herniation, Network pharmacology